Newer antiphospholipid antibodies predict adverse outcomes in patients with acute coronary syndrome

American Journal of Clinical Pathology

Volumn 132, Issue 4, 2009, Pages 613-620

  Greco, Thomas P ^a,b   Conti Kelly, Ann Marie ^a   Greco Jr , Thomas ^a   Doyle, Robin ^a   Matsuura, Eiji ^c   Anthony, J Robert ^a   Lopez, Luis R ^d  

^a ST MARY S HOSPITAL   (United States)

^b YALE UNIVERSITY   (United States)

^c OKAYAMA UNIVERSITY   (Japan)

^d Corgenix ^*  (United States)

Author keywords

Anti 2 glycoprotein i; Antiphospholipid antibodies; Coronary artery disease; Oxidized low density lipoprotein

Indexed keywords

LOW DENSITY LIPOPROTEIN; PHOSPHOLIPID ANTIBODY; BETA2 GLYCOPROTEIN 1; OXIDIZED LOW DENSITY LIPOPROTEIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROGENESIS; CONTROLLED STUDY; DISEASE SEVERITY; HUMAN; MAJOR CLINICAL STUDY; PREVALENCE; PRIORITY JOURNAL; REVASCULARIZATION; RISK FACTOR; ADOLESCENT; ANTIPHOSPHOLIPID SYNDROME; CORONARY ARTERY DISEASE; FEMALE; IMMUNOLOGY; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; ADOLESCENT; ADULT; AGED; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; CORONARY ARTERY DISEASE; FEMALE; HUMANS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 70349582320     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/AJCP2FJUT2YZGITK     Document Type: Article

References (61)

1. Lindahl B, Toss H, Siegbahn B, et al. Markers of myocardial damage and inflammation in relation to long-term morbidity and unstable coronary heart disease. N Engl J Med. 2001;343:1139-1147.
2. Packard CJ, O'Reilly DS, Caslake MJ. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. N Engl J Med. 2001;343:1148-1155.
3. Folsom AR, Chambless LE, Ballantyne CM. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers. Arch Intern Med. 2006;166:1368-1373.
4. Kitsis RN, Jialal I. Limiting myocardial damage during acute myocardial infarction by inhibiting C-reactive protein. N Engl J Med. 2006;355:513-515. (Pubitemid 44162281)
5. Rodgers G, Kopecky S. The future of cardiovascular biomarkers. Am Heart Hosp J. 2006;4:228-231.
6. Tsimikas S, Brilakais ES, Miller ER, et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary heart disease. N Engl J Med. 2005;353:46-57. (Pubitemid 41007806)
7. Vaarala O. Antiphospholipid antibodies in myocardial infarction. Lupus. 1998;7(suppl 2):S132-S134.
8. Lloyd-Jones DM, Tian L. Predicting cardiovascular risk. Arch Intern Med. 2006;166:1342-1344.
9. Brey RL, Abbott RD, Curb JD, et al. β2-glycoprotein I dependent anticardiolipin antibodies and the risk of ischemic stroke and myocardial infarction: the Honolulu Heart Program. Stroke. 2001;32:1701-1706.
10. Bili A, Moss AF, Francis CW, et al. Anticardiolipin antibodies and recurrent coronary events: a prospective study of 1150 patients. Circulation. 2000;102:1258-1263. (Pubitemid 30728124)
11. Adler Y, Finkelstein Y, Zandeman-Goddard G, et al. The presence of antiphospholipid antibodies in acute myocardial infarction. Lupus. 1995;4:309-313.
12. Sherer Y, Tenenbaum A, Praprotnik S, et al. Coronary artery disease but not coronary calcification is associated with elevated levels of cardiolipin, β2-glycoprotein I and oxidized LDL antibodies. Cardiology. 2001;95:20-24. (Pubitemid 32506956)
13. Hamsten A, Norberg R, Björkholm M, et al. Antibodies to cardiolipin in young survivors of myocardial infarction: an association with recurrent cardiovascular events. Lancet. 1986;1:113-116. (Pubitemid 16183102)
14. Chambers JD Jr, Haaire HD, Deligonul U. Multiple early percutaneous transluminal coronary angioplasty failures related to lupus anticoagulant. Am Heart J. 1996;132:189-190. (Pubitemid 26243711)
15. Morton KE, Gavaghan TP, Krilis SA, et al. Coronary artery bypass graft failure: an autoimmune phenomenon? Lancet. 1986;2:1353-1357.
16. Gurlek A, Ozdol C, Pamir G, et al. Association between anticardiolipin antibodies and recurrent cardiac events in patients with acute coronary syndrome. Int Heart J. 2005;46:631-638.
17. Niessner A, Hornykewycz S, Graf S, et al. Pre-existing anticardiolipin antibodies and development of restenosis after coronary balloon angioplasty: predictive value for a complicated course? Blood Coagul Fibrinolysis. 2004;15:311-316. (Pubitemid 38757058)
18. Chiarugi L, Prisco D, Antonucci E, et al. Lipoprotein(a) and anticardiolipin antibodies are risk factors for clinically relevant restenosis after elective balloon percutaneous transluminal coronary angioplasty. Atherosclerosis. 2001;154:129-135. (Pubitemid 32008572)
19. Ranzolin A, Bohn JM, Norman GL, et al. Anti-β2-glycoprotein I antibodies as risk factors for acute myocardial infarction. Arq Bras Cardiol. 2004;83:141-144.
20. Wu R, Nityanand S, Berglun L, et al. Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction. Arterioscler Thromb Vasc Biol. 1997;17:3159-3163. (Pubitemid 28016072)
21. Raghavan C, Ditchfield J, Taylor RJ, et al. Influence of anticardiolipin antibodies on immediate patient outcome after myocardial infarction. J Clin Pathol. 1993;46:1113-1115. (Pubitemid 24022958)
22. Sletnes KE, Smith P, Abdelnoor M, et al. Antiphospholipid antibodies after myocardial infarction and their relation to mortality, reinfarction, and non-haemorrhagic stroke. Lancet. 1992;339:451-453.
23. Phadke KV, Phillips RA, Clarke D, et al. Anticardiolipin antibodies in ischaemic heart disease: marker or myth? Br Heart J. 1993;69:391-394. (Pubitemid 23171112)
24. Tsakiris DA, Tschopl M, Jager K, et al. Anticardiolipin antibodies are not associated with restenosis or endothelial activation after percutaneous transluminal angioplasty. Int Angiol. 1997;16:88-93. (Pubitemid 27353139)
25. Lopez LR, Dier KJ, Lopez D, et al. Anti-β2-glycoprotein I and antiphosphatidylserine antibodies are predictors of arterial thrombosis in patients with antiphospholipid syndrome. Am J Clin Pathol. 2004;121:142-149. (Pubitemid 38090165)
26. Lopez D, Garcia-Valladares I, Palfox-Sanchez CA, et al. Oxidized low-density/β2-glycoprotein I complexes and autoantibodies to oxLig-1/β2-glycoprotein I in patients with systemic lupus erythematosus and antiphospholipid syndrome. Am J Clin Pathol. 2004;121:426-436. (Pubitemid 38298177)
27. Shoenfeld Y, Gerli R, Doria A, et al. Accelerated atherosclerosis in autoimmune rheumatic disease. Circulation. 2005;112:3337-3347. (Pubitemid 43739380)
28. Frostegard J. Atherosclerosis in patients with autoimmune disorders. Arterioscler Thromb Vasc Biol. 2005;25:1776-1785.
29. George J, Harats D, Gilburd B, et al. Immunolocalization of β2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression. Circulation. 1999;99:2227-2230. (Pubitemid 29201126)
30. Sherer Y, Shoenfeld Y. Antiphospholipid antibodies: are they pro-atherogenic or an epiphenomenon of atherosclerosis? Immunobiology. 2003;207:13-16. (Pubitemid 36285090)
31. Hasunuma Y, Matsuura E, Makita Z, et al. Involvement of β2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol. 1997;107:569-573. (Pubitemid 27102148)
32. Merlini PA, Bauer KA, Oltrana L, et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation. 1994;90:61-68. (Pubitemid 24203663)
33. Reber G, Cornby E, Degenne D, et al. Multicenter evaluation of nine kits for the quantitation of anticardiolipin antibodies. Thromb Haemost. 1995;52:444-452.
34. Tincani A, Spatolo L, Cattaneo R, et al. Antiphospholipid ELISA: the state of the art. Lupus. 1996;5:477-479.
35. Triplett DA. Protean clinical presentation of antiphospholipid-protein antibodies (APA). Thromb Haemost. 1995;74:329-337.
36. Cines DB, McCrae KR. The antiphospholipid-protein syndrome. J Clin Immunol. 1995;15(6 suppl):86S-100S.
37. Iverson GM, von Mühlen CA, Staub H, et al. Patients with atherosclerotic syndrome, negative in anticardiolipin assays, make IgA autoantibodies that preferentially target domain 4 of β2GPI. J Autoimmun. 2006;27:266-271. (Pubitemid 46199123)
38. Meroni PL, Peyvandi F, Foco L, et al. Anti-β2 glycoprotein I antibodies and the risk of myocardial infarction in young premenopausal women. J Thromb Haemost. 2007;5:2421-2428. (Pubitemid 350154352)
39. Gharavi AE, Wilson WA. The syndrome of thrombosis, thrombocytopenia and recurrent spontaneous abortions associated with antiphospholipid antibodies: Hughes syndrome. Lupus. 1996;5:343-344.
40. Hughes GRV. The antiphospholipid syndrome. Lupus. 1996;5:345-346.
41. Piette JC. Diagnostic and classification criteria for antiphospholipid/cofactor syndrome: a "mission impossible"? Lupus. 1996;5:354-363.
42. Petri M. Diagnosis of antiphospholipid antibodies. Rheum Dis Clin North Am. 1994;20:443-469.
43. Bick RL, Baker WF Jr. The antiphospholipid and thrombosis syndrome. Med Clin North Am. 1994;78:667-684.
44. Khamashta MA, Cuadrado NJ, Fedza M, et al. The management of thrombosis and the antiphospholipid syndrome. N Engl J Med. 1995;332:993-997.
45. Tincani AA, Biasini-Rebaioli C, Cattaneo R, et al. Nonorgan specific autoantibodies in heart damage. Lupus. 2005;14:656-659. (Pubitemid 41413285)
46. Meroni PL, Raschi E, Testoni C, et al. Antiphospholipid antibodies and the endothelium. Rheum Dis Clin North Am. 2001;27:587-602.
47. Matsuura E, Kobayashi K, Yasuda T, et al. Antiphospholipid antibodies and atherosclerosis. Lupus. 1998;7(suppl 2):S129-S135.
48. Doria A, Sherer Y, Meroni PL, et al. Inflammation and accelerated atherosclerosis: basic mechanisms. Rheum Dis Clin North Am. 2005;31:355-362. (Pubitemid 40732493)
49. Miyakis S, Gianakopoulous B, Krilis SA. β2-glycoprotein I function in health and disease. Thromb Res. 2004;114:35-46.
50. Greco TP, Amos MD, Conti-Kelly AM, et al. Testing for the antiphospholipid syndrome: importance of IgA anti-β2-glycoprotein I. Lupus. 2000;9:33-41.
51. Locht H, Wiik A. IgG and IgM isotypes of anti-cardiolipin and anti-β2-glycoprotein I antibodies reflect different forms of recent thromboembolic events. Clin Rheumatol. 2006;25:246-250. (Pubitemid 43372325)
52. Neville C, Rauch J, Kassiss J, et al. Antiphospholipid antibodies predict imminent vascular events independently from other risk factors in a prospective cohort. Thromb Haemost. 2009;101:100-107.
53. Goldberg SN, Conti-Kelly AM, Greco TP. A family study of anticardiolipin antibodies and associated clinical conditions. Am J Med. 1995;99:473-479.
54. Domenico Sebastiani G, Minisola G, Galeazzi M. HLA class II alleles and genetic predisposition to the antiphospholipid syndrome. Autoimmun Rev. 2003;2:387-394. (Pubitemid 37211394)
55. Mackworth-Young C, Chan J, Harris EN, et al. High incidence in anti-cardiolipin antibodies in relatives of patients with systemic lupus erythematosus. J Rheum. 1987;14:723-726. (Pubitemid 17137486)
56. Arnett FC, Thiagarajan P, Ahn C, et al. Associations of anti-β2-glycoprotein I autoantibodies with HLA class II alleles in three ethnic groups. Arthritis Rheum. 1999;42:268-274. (Pubitemid 29072843)
57. Granados J, Vargas-Alarcon G, Drenkard C, et al. Relationship of anticardiolipin antibodies and antiphospholipid syndrome to HLA-DR7 in Mexican patients with systemic lupus erythematosus (SLE). Lupus. 1997;6:57-62. (Pubitemid 27055736)
58. Kelishadi R, Sabet B, Khosravi A. Anticardiolipin antibody of adolescents and age of myocardial infarction in parents. Med Sci Monit. 2003;9:515-518. (Pubitemid 38009850)
59. Zethelius B, Berglund M, Sundstrom J, et al. Use of multiple biomarkers improve the prediction of death from cardiovascular causes. N Engl J Med. 2008;358:2107-2116. (Pubitemid 351679597)
60. DeLemos J, Lloyd-Jones D. Multiple biomarker panels for cardiovascular risk assessment. N Engl J Med. 2008;358:2172-2174. (Pubitemid 351679606)
61. Shlipak MG, Ix JH, Bibbins-Domingo K, et al. Biomarkers to predict recurrent cardiovascular disease: the Heart and Soul Study. Am J Med. 2008;121:50-57.